Replies to post #121295 on Anavex Life Sciences Corp (AVXL)

[polarbear77]

Thank you Investor2014 for finding that Nov 14, 2017 abstract link for Dr Francardo at the Neuroscience 2017 conference.

Below's a quick list of upcoming conferences/presentations (others?):

2017 Healthcare Conference on Sept 26, 2017, presentation by Anavex, presumably by Dr M
http://www.meetmax.com/sched/event_43291/~public/conference_presentations.html?event_id=43291&bank_access=0


The Parkinson's and Disease Therapeutics Conference
October 30, 2017
"The Parkinson's Disease Therapeutics Conference is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development."
She has one of only 8 posters at this year's event: Veronica Francardo, PhD
Lund University
ANAVEX 2-73, a clinical Alzheimer drug candidate, induces neurorestoration in experimental parkinsonism
https://www.michaeljfox.org/research/parkinsons-therapeutics-conference.html?navid=pd-therapeutics-conf


Neuroscience 2017 Conference
November 13, 2017 from 3-4p
Topic:
370.07 / C20 - Efficacy of ANAVEX 2-73, a Sigma-1 receptor agonist, in the MECP2 mouse model of Rett syndrome; Authors: J. S. SPROUSE, N. REBOWE, D. KLAMER, C. MISSLING;
Anavex Life Sci., New York, NY
https://www.abstractsonline.com/pp8/#!/4376/presentation/16595


Neuroscience 2017 Conference
November 14, 2017 from 2-3p
http://www.abstractsonline.com/pp8/#!/4376/presentation/28724
572.22 / S4 - ANAVEX 2-73, a clinical Alzheimer drug candidate, induces neurorestoration in experimental parkinsonism
Authors
*V. FRANCARDO1, F. BEZ1, J. S. SPROUSE2, C. MISSLING2, A. CENCI1;
1Lund Univ., Lund, Sweden; 2Anavex Life Sci., New York, NY
"Conclusion: Our results reveal that ANA 2-73 ameliorates motor deficits in tests assessing spontaneous rotational activity and forelimb use asymmetry, and exerts noticeable neurorestorative effects on the damaged nigrostriatal dopamine system. Further experiments are now ongoing to elucidate the mechanisms underlying these effects."


Lastly, someone on the board had posted a link to another conference in Spain? in MAY 2018? that we'd copied/pasted the below abstract from Dr Francardo as well. However I can no longer find the link to the abstract/conference to cite the below, will need to reconfirm:
"Using the same animal model of PD as in our previous study (i.e. intrastriatal 6-OHDA mouse model), we investigated the potential neurorestorative effects of ANAVEX 2-73, a compound with activity at both Sigma-1 and muscarinic receptors that is currently being tested in people affected by Alzheimer´s disease. Our results reveal that ANAVEX 2-73 is able to ameliorate parkinsonian motor symptoms in tests assessing spontaneous rotational activity and forelimb use asymmetry, and exerts neuroprotective/neurorestorative effects on the nigrostriatal dopamine system."


Listing of Dr Veronica Francardo's published work (credit to poster neiu for the link): http://portal.research.lu.se/portal/en/persons/veronica-francardo(9c206658-28b7-4a7c-a4e3-2f199ca7618a)/publications.html